Conference Coverage

DDW: SVR rates slump with real world use of sofosbuvir-based HCV regimens


 

AT DDW 2015

References

“I think some of it is people have just gotten really spoiled, and we now think that 95% treatment completion is the real world,” she said. “We just don’t see it. I think one may argue that some of the other supposed real world trials, the TARGET or TRIO trials, those generally are people getting seen at academic medical centers. … Those kinds of centers, although they’re a version of the real world, it’s not quite the same as my nurse practitioner in some of the VA clinics.”

pwendling@frontlinemedcom.com

On Twitter @pwendl

*This story was updated July 1, 2015

Pages

Recommended Reading

Norovirus outbreak likely caused by swimming in infected waters
MDedge Internal Medicine
Shortening all-oral HCV therapy feasible
MDedge Internal Medicine
DDW: Significant worker productivity gains with newer hepatitis C drugs
MDedge Internal Medicine
DDW: Menopausal hormone therapy increases major GI bleed risk
MDedge Internal Medicine
DDW: HBV, tuberculosis reactivations rare in IBD patients on biologic therapy
MDedge Internal Medicine
DDW: Recurrent C. difficile infections take heavy toll on IBD patients
MDedge Internal Medicine
FDA warns of possible dosing errors with Zerbaxa
MDedge Internal Medicine
Community-level interventions increase HPV immunization rates
MDedge Internal Medicine
Prevention measures critical in avoiding global spread of MERS
MDedge Internal Medicine
FDA report provides overview of HCV drug approvals
MDedge Internal Medicine